Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 2/20 | 0.50 |
| ▸ | ALPG | P10696 | 1/20 | 0.50 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | CDK4 | P11802 | 1/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.49 |
| ▸ | CCND1 | P24385 | 1/20 | 0.49 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.49 |
| ▸ | LIPE | Q05469 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | SGMS2 | Q8NHU3 | 3/20 | 0.45 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8488982 | 0.86 | MAPT (0.51) | MAPTMAPK1TDP1L3MBTL1HTR1A | |
| SCHEMBL6539340 | 0.81 | CYP11B1 (0.45) | HTR1ADRD2NPC1 | |
| SCHEMBL7284996 | 0.81 | MAOB (0.62) | MAPTL3MBTL1MAOB | |
| SCHEMBL6161980 | 0.81 | MAPT (0.53) | MAPTMAPK1TDP1L3MBTL1HTR1A | |
| SCHEMBL31139621 | 0.81 | MAPT (0.53) | MAPTMAPK1TDP1L3MBTL1HTR1A | |
| SCHEMBL448079 | 0.81 | MAOB (0.57) | MAPTMAPK1TDP1L3MBTL1HTR1A | |
| SCHEMBL6539635 | 0.80 | IDO1 (0.47) | DRD2NPC1MAOB | |
| SCHEMBL692157 | 0.79 | ALOX5 (0.50) | MAPTMAPK1TDP1L3MBTL1ALPG | |
| SCHEMBL6538639 | 0.79 | FFAR1 (0.45) | L3MBTL1 | |
| SCHEMBL339812 | 0.79 | MAPT (0.71) | MAPTMAPK1TDP1L3MBTL1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249116-B2 | Enzyme-activating compounds and compositions | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-02-02 | — | — | US | claimed |
| CN-103554040-B | A kind of preparation method of deferasirox derivative | NANJING JINGLONG DRUG RESEARCH AND DEVELOPMENT CO., LTD. (CN) | 2015-12-02 | — | — | CN | claimed |
| US-20150210659-A1 | PARTICULATE DRUG DELIVERY METHODS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-07-30 | — | — | US | claimed |
| EP-0983228-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-08-07 | — | — | EP | claimed |
| JP-2002523448-A | — | — | 2002-07-30 | — | — | JP | claimed |
| US-6410540-B1 | HEART AND KIDNEY DISEASES; ANTIINFLAMMATORY AGENTS | SCIOS, INC. | 2002-06-25 | — | — | US | claimed |
| US-20020065230-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-05-30 | — | — | US | claimed |
| EP-1107758-A2 | USE OF PIPERIDINES AND/OR PIPERAZINES AS INHIBITORS OF P38-ALPHA KINASE | SCIOS INC. (US) | 2001-06-20 | — | — | EP | claimed |
| CN-1255119-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2000-05-31 | — | — | CN | claimed |
| WO-2000012074-A2 | USE OF PIPERIDINES AND/OR PIPERAZINES AS INHIBITORS OF P38-ALPHA KINASE | SCIOS INC. (US) | 2000-03-09 | — | — | WO | claimed |
| EP-0983228-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-03-08 | — | — | EP | claimed |
| WO-1998050342-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-12 | — | — | WO | claimed |
| WO-1998025949-A1 | SUBSTITUTED 5-AMINO-1,3,4-THIADIAZOLE-2-THIONES | PROSCRIPT, INC. (US) | 1998-06-18 | — | — | WO | claimed |
| EP-0845002-A2 | AMINO ACID AMIDES OF 5-AMINO-1,3,4-THIADIAZONES AND THEIR USE AS INHIBITORS FOR MATRIX METALLOPROTEINASES | PROSCRIPT, INC. (US) | 1998-06-03 | — | — | EP | claimed |
| US-5677282-A | ENZYME INHIBITOR; OSTEOARTHRITIS AND RHEUMATIC DISORDERS | PROSCRIPT, INC. (US) | 1997-10-14 | — | — | US | claimed |
| WO-1996040745-A2 | AMINO ACID AMIDES OF 5-AMINO-1,3,4-THIADIAZONES AND THEIR USE AS INHIBITORS FOR MATRIX METALLOPROTEINASES | PROSCRIPT, INC. (US) | 1996-12-19 | — | — | WO | claimed |
| US-4539155-A | New peptide, process for preparation thereof and use thereof | FUISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1985-09-03 | — | — | US | claimed |
| JP-59155372-A | — | — | None | — | — | JP | disclosed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
| JP-S59155372-A | 6,7-DIMETHOXYQUINAZOLINE DERIVATIVE | SANKYO CO LTD | 1984-09-04 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065230-A1 | Protease inhibitors | PRSS1, DNPEP, CTSZ | MAPT 3494/4885MAPK1 3923/4885TDP1 1610/4885 |
| US-20150210659-A1 | PARTICULATE DRUG DELIVERY METHODS | CASP3, BAX, CASP5 | MAPT 2006/4885MAPK1 3832/4885TDP1 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.